We are live on ! Find out more
NM

Newtyn Management Portfolio holdings

AUM $801M
1-Year Est. Return 23.14%
This Fund
S&P 500
This Quarter Est. Return
+11.59%
1 Year Est. Return
+23.14%
3 Year Est. Return
+51.97%
5 Year Est. Return
+52.71%
10 Year Est. Return
+183.03%
AUM
$509M
AUM Growth
+$104M
Cap. Flow
+$50.7M
Cap. Flow %
9.95%
Top 10 Hldgs %
65.66%
Holding
55
New
9
Increased
21
Reduced
8
Closed
7

Top Buys

Rank Stock Value
1
MDRX
Veradigm Inc. Common Stock
MDRX
+$17.9M
2
PPLI
People Inc
PPLI
+$13.4M
3
OFIX icon
Orthofix Medical
OFIX
+$12.4M
4
MITK icon
Mitek Systems
MITK
+$11.1M
5
CNNE icon
Cannae Holdings
CNNE
+$10.2M

Top Sells

Rank Stock Value
1
AMBP icon
Ardagh Metal Packaging
AMBP
+$16.4M
2
TSVT
2seventy bio
TSVT
+$12.1M
3
PFSW
PFSweb, Inc.
PFSW
+$5.3M
4
TLYS icon
Tilly's
TLYS
+$4.82M
5
DXLG icon
Destination XL Group
DXLG
+$2.69M

Sector Composition

Rank Sector Weight
1 Healthcare 25.55%
2 Consumer Discretionary 22.11%
3 Technology 12.87%
4 Communication Services 12.45%
5 Real Estate 7.75%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
FET icon
26
Forum Energy Technologies
FET
$907M
$4.31M 0.85%
194,300
+11,000
+6% +$247K
TECX
27
Tectonic Therapeutic
TECX
$696M
$3.72M 0.73%
227,848
+61,181
+37% +$1.05M
ETNB
28
DELISTED
89bio
ETNB
$3.04M 0.6%
272,500
+72,000
+36% +$662K
MURA
29
DELISTED
Mural Oncology
MURA
$2.63M 0.52%
+445,000
New +$1.79M
WVE icon
30
Wave Life Sciences
WVE
$993M
$2.58M 0.51%
510,000
– –
OLMA icon
31
Olema Pharmaceuticals
OLMA
$899M
$2.1M 0.41%
150,000
– –
BOLT icon
32
Bolt Biotherapeutics
BOLT
$7.34M
$1.74M 0.34%
77,677
+26,677
+52% +$519K
ADPT icon
33
Adaptive Biotechnologies
ADPT
$4.02B
$1.58M 0.31%
+322,000
New +$1.47M
AVIR icon
34
Atea Pharmaceuticals
AVIR
$430M
$1.55M 0.3%
508,474
+108,474
+27% +$329K
VNDA icon
35
Vanda Pharmaceuticals
VNDA
$320M
$1.22M 0.24%
+290,000
New +$1.17M
FTH
36
Faeth Therapeutics
FTH
$874M
$1.09M 0.21%
78,601
-11,399
-13% -$156K
QTTB icon
37
Q32 Bio
QTTB
$447M
$851K 0.17%
+77,737
New +$1.14M
ALGS icon
38
Aligos Therapeutics
ALGS
$43.1M
$833K 0.16%
50,200
+13,400
+36% +$230K
BDTX icon
39
Black Diamond Therapeutics
BDTX
$128M
$787K 0.15%
280,000
+75,000
+37% +$176K
NBBK icon
40
NB Bancorp
NBBK
$984M
$631K 0.12%
+46,945
New +$639K
ADVM
41
DELISTED
Adverum Biotechnologies
ADVM
$620K 0.12%
82,310
-20,190
-20% -$184K
TLYS icon
42
Tilly's
TLYS
$121M
$473K 0.09%
62,784
-599,463
-91% -$4.82M
ORKA
43
Oruka Therapeutics
ORKA
$6.03B
$458K 0.09%
22,443
-2,557
-10% -$57.4K
DFNS
44
T3 Defense Inc
DFNS
$12.3M
$76.9K 0.02%
+27
New +$197K
ARIZR
45
DELISTED
Arisz Acquisition Corp. Right
ARIZR
$52.5K 0.01%
250,000
– –
VHAQ.RT
46
DELISTED
Viveon Health Acquisition Corp. Rights, each exchangeable into one-twentieth of a share of Common Stock
VHAQ.RT
$11.3K ﹤0.01%
250,000
– –
LFLYW
47
DELISTED
Leafly Holdings, Inc. Warrant
LFLYW
$9.96K ﹤0.01%
634,640
– –
DXLG icon
48
Destination XL Group
DXLG
$34.3M
– –
-600,000
Closed -$2.69M
MRSN
49
DELISTED
Mersana Therapeutics
MRSN
– –
-28,000
Closed -$889K
ONL
50
Orion Office REIT
ONL
$162M
– –
-474,721
Closed -$2.47M
1
2
3

Similar funds

LWM
Liberty Wealth Management Oakland, California $800M AUM 22.73% 1-Year Est. Return
CCM
Corsair Capital Management New York $800M AUM 94.38% 1-Year Est. Return
HW
HORAN Wealth Cincinnati, Ohio $800M AUM 23.65% 1-Year Est. Return
LOPW
Live Oak Private Wealth Wilmington, North Carolina $800M AUM 24.59% 1-Year Est. Return
BBPWM
Blue Bell Private Wealth Management Blue Bell, Pennsylvania $802M AUM 22.13% 1-Year Est. Return
WLIM
White Lighthouse Investment Management Bedford, Massachusetts $802M AUM 19.15% 1-Year Est. Return
KFAA
Klaas Financial Asset Advisors Loves Park, Illinois $803M AUM 13.2% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return

Newtyn Management's Q4 2023 Portfolio in Review

As of Q4 2023, Newtyn Management held 55 positions worth $509M, up 26% from $405M the previous quarter. Its ten largest holdings account for 66% of the portfolio.

Newtyn Management deployed $50.7M of net new capital in Q4 2023, opening 9 new positions and adding to 21 existing holdings. Its largest new stake was Veradigm Inc. Common Stock: 1,461,692 shares worth $15.3M.

By sector, the portfolio is most concentrated in Healthcare at 26% of assets, up from 24% a quarter earlier, followed by Consumer Discretionary and Technology.

On the sell side, the largest reduction was Ardagh Metal Packaging, an estimated $16.4M trimmed.

  • Newtyn Management's largest Q4 2023 buy was Veradigm Inc. Common Stock: 1,461,692 shares worth $15.3M.
  • Newtyn Management added most to People Inc in Q4 2023, an estimated $13.4M increase.
  • Newtyn Management's biggest Q4 2023 reduction was Ardagh Metal Packaging, cutting an estimated $16.4M.
  • Newtyn Management fully exited 2seventy bio in Q4 2023, selling an estimated $12.1M.
  • Newtyn Management's ten largest holdings make up 66% of its $509M portfolio in Q4 2023.
  • Newtyn Management opened 9 new positions and closed 7 in Q4 2023.
  • Newtyn Management's portfolio value rose 26% quarter-over-quarter to $509M.

Based on Newtyn Management's 13F filing for Q4 2023, filed 14 Feb 2024.